Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexza Pharmaceutica (ALXA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 20,340
  • Shares Outstanding, K 21,750
  • Annual Sales, $ 5,030 K
  • Annual Income, $ -21,310 K
  • 36-Month Beta 0.75
  • Price/Sales 4.05
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.81
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/04/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9020 +10.86%
on 06/17/16
1.0300 -2.91%
on 05/25/16
+0.0800 (+8.70%)
since 05/20/16
3-Month
0.4300 +132.56%
on 04/05/16
1.0300 -2.91%
on 05/25/16
+0.4400 (+78.57%)
since 03/21/16
52-Week
0.2200 +354.55%
on 02/09/16
1.6000 -37.50%
on 09/25/15
-0.2600 (-20.63%)
since 06/19/15

Most Recent Stories

More News
Galen US Inc. Acquires First Inhaled Therapy Approved to Treat Agitation Associated with Schizophrenia and Bipolar I Disorder, Announces Revised Labeling

Galen US Inc. today announced its acquisition of the US commercial rights to ADASUVE(R), an orally inhaled form of the typical antipsychotic loxapine, from Alexza Pharmaceuticals, Inc. ADASUVEis...

ALXA : 1.0000 (+6.95%)
Galen US Inc. Acquires First Inhaled Therapy Approved to Treat Agitation Associated with Schizophrenia and Bipolar I Disorder, Announces Revised Labeling

Galen US Inc. today announced its acquisition of the US commercial rights to ADASUVE(R), an orally inhaled form of the typical antipsychotic loxapine, from Alexza Pharmaceuticals, Inc. ADASUVEis...

ALXA : 1.0000 (+6.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 1.0000
1st Resistance Point 1.0000
Last Price 1.0000
1st Support Level 1.0000
2nd Support Level 1.0000

See More

52-Week High 1.6000
Fibonacci 61.8% 1.0728
Last Price 1.0000
Fibonacci 50% 0.9100
Fibonacci 38.2% 0.7472
52-Week Low 0.2200

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.